Holen Sie sich die Stockscreener-App
19.72
7.59%
-1.62
Handel nachbörslich:
19.72
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' (SRPT) Narrative? - simplywall.st
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management? - Yahoo Finance
Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo - The Globe and Mail
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Action & Entry Point Confirmation Alerts - BỘ NỘI VỤ
Sarepta (SRPT) gets FDA approval on new gene therapy study - Investorsobserver
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Tech Stocks Surge Ahead Of Thanksgiving, Robinhood Rallies 10%: What's Moving Markets Wednesday? - Benzinga
Sarepta cleared to test new safety regimen for Duchenne drug - statnews.com
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs - Yahoo
Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline - TipRanks
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit (PR Newswire) - Aktiellt
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Sarepta to test immunosuppressive Elevidys regimen in non-ambulatory DMD patients - FirstWord Pharma
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF - CGTLive®
Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction - Fierce Pharma
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Yahoo Finance
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges - TipRanks
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk - Benzinga
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Lelezard
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - Stocktwits
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study - GuruFocus
Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy - MarketScreener
Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression - StreetInsider
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Bernstein raises Sarepta Therapeutics stock price target to $20 on DMD estimates - Investing.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments - TipRanks
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone - Fierce Biotech
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT) - Sahm
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - BioSpace
Arrowhead (ARWR) Secures $200M Milestone Payment from Sarepta - GuruFocus
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment By Investing.com - Investing.com South Africa
Sarepta provides progress update for SRP-1003, its treatment for myotonic dystrophy type 1 - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment - Investing.com
Sarepta advances SRP-1003 trial, triggers $200 million milestone payment - StreetInsider
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 - Sarepta Therapeutics
Sarepta terminates Hansa-partnered gene therapy combination trial - Clinical Trials Arena
Tangible book value per share of Sarepta Therapeutics, Inc. – TRADEGATE:AB3A - TradingView
Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings - simplywall.st
Is Sarepta Therapeutics Inc. stock overvalued by current metricsGap Down & Low Drawdown Momentum Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
In new FDA role, Pazdur will decide the future of Sarepta’s Duchenne drugs - statnews.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Weekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating - Investing.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Why Sarepta Therapeutics Inc. (AB3A) stock signals breakout potentialJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Sarepta Therapeutics Inc. stock trend forecastJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
[Form 4] Sarepta Therapeutics, Inc. Insider Trading Activity - Stock Titan
Relative strength of Sarepta Therapeutics Inc. in sector analysisJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com
SAREPTA THERAPEUTICS INC (SRPT.MX) stock major holders - Yahoo Finance UK
Is Sarepta Therapeutics Inc. stock ready for a breakoutMarket Growth Report & Low Volatility Stock Recommendations - newser.com
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Rate Hike & Safe Capital Growth Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock profit from AI boomRecession Risk & Fast Moving Stock Watchlists - newser.com
Is Sarepta Therapeutics Inc. stock attractive for growth ETFs2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
0.30%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):